Pristiq is an antidepressant medication.
Pristiq is a specific antidepressant chemically unrelated to any class of antidepressant drugs (tricyclic, tetracyclic, or other), and is a combination of two pharmacologically active enantiomers.
Pristiq heat does not depend on food intake. The total bioavailability of the substance is 40–45% and is due to intensive pre-systemic metabolism in the liver. The degree of binding of venlafaxine and EFA with plasma proteins is 27% and 30%, respectively. Both Pristiq and its main metabolite pass into breast milk. When Pristiq is taken in a daily dose, varying from 75 to 450 mg, the drug itself differ in their linear pharmacokinetics. The maximum concentration of Pristiq in the blood plasma is achieved in 2 and 3 hours, respectively, when taken orally. When taking prolonged forms of Pristiq, the time to reach the maximum concentration increases to 5.5 and 9 hours, respectively.
The age and sex of patients do not significantly affect the pharmacokinetic parameters of Pristiq. The need for special dose adjustment for elderly patients absents.
The metabolism of venlafaxine is reduced, and their maximum concentrations are increased. For patients with QA less than 30 ml/min, the reduction in the total clearance of Pristiq is most pronounced. For patients on renal hemodialysis, the half-life increases by 180% for venlafaxine, and the clearance of both active components is reduced by 57%. For such patients, especially those undergoing hemodialysis, an individual selection of the dose of the drug and control of its pharmacokinetic parameters is recommended, taking into account the duration of the course of therapy.